Viazis Nikos, Karamanakos Anastasios, Mousourakis Konstantinos, Christidou Angeliki, Fousekis Fotios, Mpakogiannis Konstantinos, Koukoudis Anastasios, Katsanos Konstantinos, Christodoulou Dimitrios, Cheila Myrto, Tzouvala Maria, Zacharopoulou Eirini, Palatianou Maria, Giouleme Olga, Katsoula Anastasia, Liatsos Christos, Kyriakos Nikolaos, Zampeli Evi, Papathanasiou Evgenia, Theodoropoulou Angeliki, Karmiris Konstantinos, Psaroudakis Ioannis, Tribonias George, Gazi Souzanna, Mole Evangelia, Dimitroulas Theodoros, Koutsianas Christos, Vassilopoulos Dimitris, Fragoulis George E, Michalakeas Nikos, Papagoras Charalampos, Panagakis Pantelis, Papoutsaki Marina, Chasapi Vasiliki, Stratigos Alexandros, Katsikas George
Gastroenterology Department, Evangelismos General Hospital, Athens, Greece.
Rheumatology Department, Evangelismos General Hospital, Athens, Greece.
Front Med (Lausanne). 2025 May 16;12:1583401. doi: 10.3389/fmed.2025.1583401. eCollection 2025.
To report on the efficacy and safety of elective switching from intravenously (IV) to subcutaneously (SC) administered Infliximab (IFX) in patients with immune mediated diseases.
Retrospective analysis of patients with Crohn's disease (CD), Ulcerative Colitis (UC), Spondyloarthritis (SpA), Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and chronic plaque Psoriasis (PsO) who were receiving IFX-IV for maintenance of remission in tertiary referral centers and were switched to IFX-SC based on their physician's choice. All patients with gastrointestinal and skin diseases were in clinical remission, while those with musculoskeletal disease had inactive disease or low disease activity. The primary endpoint was disease deterioration during a follow up period, of at least 6 months, according to disease specific composite measures.
Between April 2023 and April 2024, a total of 344 patients (CD = 136, UC = 62, SpA = 52, PsA = 38, RA = 7, PsO = 44, co-existence of more than one disease = 5) were switched from IFX-IV to IFX-SC. After a mean±SD follow up period of 8 ± 4 months, 12 patients (3.5%) discontinued treatment with IFX-SC. Five of them (1.5%) because of disease worsening and the remaining 7 (2.0%) because of the occurrence of side effects. All 332 other patients (96.5%) showed favorable response, none of them requested an unscheduled visit, or developed an adverse event (clinical or laboratory) or needed escalation of treatment.
Elective switching from IFX-IV to IFX-SC seems to be an effective and safe approach in real-world every day clinical practice to maintain long-term clinical remission, inactive disease or low disease activity in patients with immune-mediated diseases.
报告在免疫介导疾病患者中，选择性地将英夫利昔单抗（IFX）的给药方式从静脉注射（IV）转换为皮下注射（SC）的疗效和安全性。
对在三级转诊中心接受IFX-IV维持缓解治疗、后根据医生选择转换为IFX-SC的克罗恩病（CD）、溃疡性结肠炎（UC）、脊柱关节炎（SpA）、类风湿关节炎（RA）、银屑病关节炎（PsA）和慢性斑块状银屑病（PsO）患者进行回顾性分析。所有患有胃肠道和皮肤疾病的患者均处于临床缓解期，而患有肌肉骨骼疾病的患者病情不活跃或疾病活动度较低。主要终点是根据疾病特异性综合指标，在至少6个月的随访期内疾病恶化情况。
在2023年4月至2024年4月期间，共有344例患者（CD = 136例，UC = 62例，SpA = 52例，PsA = 38例，RA = 7例，PsO = 44例，合并一种以上疾病 = 5例）从IFX-IV转换为IFX-SC。在平均±标准差为8±4个月的随访期后，12例患者（3.5%）停止了IFX-SC治疗。其中5例（1.5%）是因为疾病恶化，其余7例（2.0%）是因为出现了副作用。其他332例患者（96.5%）均显示出良好反应，无一例要求非计划就诊，或出现不良事件（临床或实验室），或需要加强治疗。
在现实世界的日常临床实践中，选择性地将IFX-IV转换为IFX-SC似乎是一种有效且安全的方法，可维持免疫介导疾病患者的长期临床缓解、病情不活跃或低疾病活动度。
